BioSpace News Archive

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that the European Commission has approved Ogluo™ injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, will publish its year-end report for 2020 on February 26, 2021, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.

Data Include Positive Safety and Tolerability Profile, and Preliminary Efficacy Results for Boosted Oral Formulation of Docetaxel

Takeda Pharmaceutical Company Limited at the 2021 Transplantation & Cellular Therapy Meetings Digital Experience announced new, late-breaking Phase 3 data from the TAK-620-303 trial, for the investigational drug TAK-620 which met its primary endpoint of superiority compared to conventional antiviral therapies in transplant recipients with refractory, with or without resistance, cytomegalovirus infection/disease.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precision Oncology Day, which is being held February 17, 2021.

ImmunoGen - Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Funds Operations into the Second Half of 2022 Conference Call to be Held at 8:00 a.m. ET Today

European Commission Approves Seagen’s TUKYSA ® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer - Approved for Adult Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Anti-HER2 Treatment Regimens -

OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the upcoming virtual investor conferences:

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris ® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments.

FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences